Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 22, 2015 (11 years ago)

Extended Phenytoin Sodium Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Firm did not adequately investigate customer complaints.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Extended Phenytoin Sodium Capsules, USP, 100 mg Capsules, Packaged as A) 100 Count Bottles (NDC: 64679-720-01) and B) 1000 Count Bottles (NDC: 64679-720-02), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.

Affected NDCs 64679-0720-01 64679-0720-02

Compare with the code on your package — it is the most precise check available.

Drug: Phenytoin

Recalling firm
Wockhardt Usa Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1246-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenytoin recalls

See all
Class I · High risk

Phenytoin Oral Suspension

Failed Content Uniformity Specifications

Terminated Wrong potency / content The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7079-24 D-0153-2024
Class II · Moderate risk

Extended Phenytoin Sodium Capsules

Failed Dissolution Specifications: Out-of-specification results for dissolution (above specification)

Terminated Dissolution failure Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0876-2023
Class III · Low risk

Phenytoin Sodium Injection

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Terminated Labeling / mix-up Acella Pharmaceuticals, LLC NDC 42192-614-05 D-0070-2023
Class III · Low risk

Phenytoin Sodium Injection

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Terminated Labeling / mix-up Acella Pharmaceuticals, LLC NDC 42192-614-02 D-0069-2023

Other recalls by Wockhardt Usa Inc.

All 2015 recalls
Class III · Low risk

Enalapril Maleate tablets

Failed Impurities/Degradation Specifications: 5mg strength being recalled for out of specification results for related compound.

Terminated Impurity / degradation Wockhardt Usa Inc. D-0051-2018
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: An FDA inspection identified inadequate investigations of past market complaints.

Terminated cGMP deviation Wockhardt Usa Inc. NDC 64679-941-06 D-1347-2015